Medical Xpress August 15, 2024

Danish drugmaker Bavarian Nordic said Thursday it was ready to produce up to 10 million doses of its vaccine targeting mpox by 2025 after the World Health Organization declared a surge in the virus in Africa a global public health emergency.

Alarmed by a rise in cases in the Democratic Republic of Congo and the spread of mpox to nearby countries, WHO experts said Wednesday that the “situation constitutes a public health emergency of international concern”.

“We have additional manufacturing capacity of two million doses for 2024 and (a total of) 10 million doses by 2025,” Rolf Sass Sorensen, vice-president of Bavarian Nordic, told AFP.

The company is awaiting orders from the countries concerned before starting manufacturing. “We need to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Answer ALS, Cedars-Sinai Collaboration, Single-Cell Protein Profiling, ChapsVision Acquires Sinequa, More

Share This Article